COSCIENS Biopharma (CSCI) 6-K 9 Nov 23 Current report (foreign) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) $ in Thousands, € in Millions	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Current assets
Cash and cash equivalents	$ 38,756	$ 50,611
Trade and other receivables	546	732
Inventory	91	229
Income taxes receivable	116	1,428
Prepaid expenses and other current assets	2,402	2,488
Total current assets	41,911	55,488
Non-current assets
Restricted cash equivalents	320	322
Property and equipment	255	216
Total non-current assets	575	538
Total assets	42,486	56,026
Current liabilities
Payables and accrued liabilities	3,300	3,828
Provisions	56	45
Income taxes payable	106	108
Deferred revenues (note 3)	90	2,949
Deferred gain (note 4)	529
Lease liabilities	147	114
Total current liabilities	4,228	7,044
Non-current liabilities
Deferred revenues (note 3)	1,647	1,684
Deferred gain (note 4)		110
Lease liabilities	70	65
Employee future benefits (note 5)	10,105	11,159
Provisions	158	188
Total non-current liabilities	11,980	13,206
Total liabilities	16,208	20,250
Shareholders’ equity
Share capital (note 6)	293,410	293,410
Warrants	5,085	5,085
Contributed surplus	90,682	90,332
Deficit	(362,088)	(352,084)
Accumulated other comprehensive loss	(811)	(967)
Total Shareholders’ equity	26,278	35,776
Total liabilities and shareholders’ equity	$ 42,486	$ 56,026

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Issued capital [member]	Warrants [member]	Other equity interest [member]	Retained earnings [member]	Accumulated other comprehensive income [member]	Total
Balance at Dec. 31, 2021	$ 293,410	$ 5,085	$ 89,788	$ (334,619)	$ (678)	$ 52,986
IfrsStatementLineItems [Line Items]
Net loss				(10,276)		(10,276)
Foreign currency translation adjustments					(26)	(26)
Actuarial gain on defined benefit plans				6,231		6,231
Comprehensive income (loss)				(4,045)	(26)	(4,071)
Share-based compensation costs			503			503
Balance at Sep. 30, 2022	293,410	5,085	90,291	(338,664)	(704)	49,418
Balance at Dec. 31, 2022	293,410	5,085	90,332	(352,084)	(967)	35,776
IfrsStatementLineItems [Line Items]
Net loss				(10,917)		(10,917)
Foreign currency translation adjustments					156	156
Actuarial gain on defined benefit plans				913		913
Comprehensive income (loss)				(10,004)	156	(9,848)
Share-based compensation costs			350			350
Balance at Sep. 30, 2023	$ 293,410	$ 5,085	$ 90,682	$ (362,088)	$ (811)	$ 26,278

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Profit or loss [abstract]
Revenues (note 3)	$ 3	$ 1,860	$ 4,377	$ 3,155
Expenses
Cost of sales	11	14	167	106
Research and development	2,751	3,293	9,692	8,081
Selling, general and administrative	1,791	2,274	6,130	6,218
Total expenses	4,553	5,581	15,989	14,405
Loss from operations	(4,550)	(3,721)	(11,612)	(11,250)
Gain (loss) due to changes in foreign currency exchange rates	(12)	301	(44)	977
Interest income	419		739
Other finance costs	(2)			(3)
Net finance income	405	301	695	974
Loss before income taxes	(4,145)	(3,420)	(10,917)	(10,276)
Income tax recovery
Net loss	(4,145)	(3,420)	(10,917)	(10,276)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	323	(105)	156	(26)
Items that will not be reclassified to profit or loss:
Actuarial gain (loss) on defined benefit plans (note 5)	993	(1,794)	913	6,231
Comprehensive loss	$ (2,829)	$ (5,319)	$ (9,848)	$ (4,071)
Basic loss per share (note 7)	$ (0.85)	$ (0.70)	$ (2.25)	$ (2.12)
Diluted loss per share (note 7)	$ (0.85)	$ (0.70)	$ (2.25)	$ (2.12)
Weighted average number of shares outstanding, basic	4,855,876	4,855,876	4,855,876	4,855,876
Weighted average number of shares outstanding, diluted	4,855,876	4,855,876	4,855,876	4,855,876

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss for the period	$ (4,145)	$ (3,420)	$ (10,917)	$ (10,276)
Items not affecting cash and cash equivalents:
Provisions	(20)	7	(10)	12
Depreciation and amortization	42	33	126	104
Share-based compensation costs	27	443	350	503
Employee future benefits	132	69	397	266
Amortization of deferred revenues		(1,248)	(1,554)	(1,952)
Net foreign exchange differences	(3)		(4)
Other non-cash items	2	3	7	3
Refund of income taxes	675		1,322	830
Changes in operating assets and liabilities (note 7)	(94)	168	(1,455)	254
Net cash used in operating activities	(3,384)	(3,945)	(11,738)	(10,256)
Cash flows from financing activities
Payments on lease liabilities	(33)	(33)	(113)	(101)
Net cash used in financing activities	(33)	(33)	(113)	(101)
Cash flows from investing activities
Purchase of property and equipment	(9)	(9)	(14)	(57)
Change in restricted cash equivalents	(1)	4	(1)	4
Net cash used in investing activities	(10)	(5)	(15)	(53)
Effect of exchange rate changes on cash and cash equivalents	(3)	(358)	11	(1,074)
Net change in cash and cash equivalents	(3,430)	(4,341)	(11,855)	(11,484)
Cash and cash equivalents – Beginning of period	42,186	58,157	50,611	65,300
Cash and cash equivalents – End of period	$ 38,756	$ 53,816	$ 38,756	$ 53,816

Business overview

Business overview	9 Months Ended
	Sep. 30, 2023
Business Overview
Business overview	1. Business overview Summary of business Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen ® The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on November 8, 2023.

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2023
Basis Of Presentation
Basis of presentation	2. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022. The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements. New standards and amendments Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements. Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue [abstract]
Revenue	3. Revenue The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ License fees - 605 1,554 831 Development services - 1,202 2,741 2,091 Product sales - - - 57 Royalties 3 14 29 57 Supply chain - 39 53 119 Total revenue 3 1,860 4,377 3,155 The Company recorded revenue for the transfer of services over time for the three months ended September 30, 2023, nil 1,807 4,295 2,922 3 53 82 233 Pharmanovia: On March 15, 2023, with the Company’s consent, Consilient Health (“CH”) entered into an assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product (together, the “Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. Subsequent to the execution of the Assignment Agreement, the aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations was $ 1,658 1,540 1,233 1,145 425 395 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Novo Nordisk Health Care AG: On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination was effective May 23, 2023, upon the completion of a 270-day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment returned to the Company, and the Company regained full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270-day notice period, as per the terms of the Novo Amendment, Novo continued to fund DETECT-trial costs up to $ 10.1 9.4 Liabilities related to contracts with customers The following table provides a summary of deferred revenue balances: Summary of deferred revenue September 30, 2023 Current Non-current Total $ $ $ Novo Nordisk Health Care - - - Pharmanovia 82 1,528 1,610 NK Meditech 8 119 127 90 1,647 1,737 December 31, 2022 Current Non-current Total $ $ $ Novo Nordisk Health Care 2,914 - 2,914 Consilient Health 35 1,556 1,591 NK Meditech - 128 128 2,949 1,684 4,633

Deferred gain

Deferred gain	9 Months Ended
	Sep. 30, 2023
Deferred Gain
Deferred gain	4. Deferred gain On August 10, 2021, the Company entered into a trademark maintenance and assignment option agreement with ARES Trading SA, a subsidiary of Merck KGaA (“Merck”), with respect to the trademarks owned by the Company on Cetrotide ® 529 0.5 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Employee future benefits

Employee future benefits	9 Months Ended
	Sep. 30, 2023
Employee Future Benefits
Employee future benefits	5. Employee future benefits The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset benefit plans benefit plans Total Total Nine months ended September 30, 2023 Year ended December 31, 2022 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 21,657 93 21,750 29,412 Current service cost 89 11 100 142 Interest cost 599 1 600 295 Actuarial gain from changes in financial assumptions (1,249 ) (1 ) (1,250 ) (5,915 ) Benefits paid (560 ) - (560 ) (752 ) Impact of foreign exchange rate changes (295 ) (2 ) (297 ) (1,432 ) Balances – End of the period 20,241 102 20,343 21,750 Change in plan assets Balances – Beginning of the period 10,591 - 10,591 11,927 Interest income from plan assets 296 - 296 120 Employer contributions 25 - 25 45 Employee contributions 7 - 7 10 Benefits paid (198 ) - (198 ) (247 ) Remeasurement of plan assets - - - (641 ) Change in asset ceiling (337 ) - (337 ) - Impact of foreign exchange rate changes (146 ) - (146 ) (623 ) Balances – End of the period 10,238 - 10,238 10,591 Net liability of the unfunded plans 10,003 102 10,105 10,787 Net liability of the funded plans - - - 372 Net amount recognized as Employee future benefits 10,003 102 10,105 11,159 Amounts recognized: In net loss 385 12 397 295 Actuarial gain on defined benefit plans in other comprehensive loss 912 1 913 5,262 The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 4.20 3.75 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Shareholders_ equity

Shareholders’ equity	9 Months Ended
	Sep. 30, 2023
Shareholders Equity
Shareholders’ equity	6. Shareholders’ equity Share capital The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. Summary of share capital Common shares Amount # $ Balance – December 31, 2022 4,855,876 293,410 - - Balance – September 30, 2023 4,855,876 293,410 On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of incorporation to effect a 1-for-25 1-for-25 Accordingly, all common shares, DSU, warrants, stock options and per share amounts in these interim condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share consolidation (reverse split). Share-based compensation On January 17, 2023, the Company granted 14,000 2,000 Summary of assumptions to determine share-based compensation costs over the life of awards September 30, 2023 September 30, 2022 Expected dividend yield $ 0.00 $ 0.00 Expected volatility 104.46 % 115.75 % Risk-free annual interest rate 3.56 % 1.59 % Expected life (years) 5.45 5.72 Share price $ 3.75 $ 8.88 Exercise price $ 3.75 $ 8.88 Grant date fair value $ 2.99 $ 7.47 The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) The compensation expense for the three months ended September 30, 2023, was $ 27 43 66 101 Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – January 1, 2023 42,030 20.05 Granted 14,000 3.75 Cancelled / Forfeited (400 ) 87.00 Balance – September 30, 2023 55,630 15.47 Stock options Weighted average exercise price # $ Balance – January 1, 2022 43,455 22.00 Granted 2,000 8.88 Cancelled / Forfeited (2,399 ) 10.98 Balance – September 30, 2022 43,056 21.95 Deferred share units On June 14, 2023, the Company granted 100,000 80,000 284 402 Summary of DSU activity 2023 2022 # # Balance – January 1, 96,920 16,920 Granted 100,000 80,000 Balance – September 30, 196,920 96,920 Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	9 Months Ended
	Sep. 30, 2023
Supplemental Disclosure Of Cash Flow Information
Supplemental disclosure of cash flow information	7. Supplemental disclosure of cash flow information Disclosure of changes in operating assets and liabilities 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables (411 ) 205 (9 ) 425 Inventory (1 ) 41 139 (165 ) Prepaid expenses and other current assets 186 (481 ) 64 (1,240 ) Payables and accrued liabilities (159 ) (133 ) (322 ) (14 ) Deferred revenues (27 ) 595 (1,386 ) 1,425 Taxes payable - 210 - 210 Provision for restructuring and other costs (6 ) - (11 ) - Employee future benefits (142 ) (269 ) (396 ) (387 ) Deferred gain 466 - 466 - Increase (decrease) in operating assets and liabilities (94 ) 168 (1,455 ) 254

Net loss per share

Net loss per share	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share
Net loss per share	8. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Net loss (4,145 ) (3,420 ) (10,917 ) (10,276 ) Basic and diluted weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic and diluted loss per share (0.85 ) (0.70 ) (2.25 ) (2.12 ) Basic loss per share (0.85 ) (0.70 ) (2.25 ) (2.12 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 252,550 142,375 252,550 142,375 Warrants 457,648 457,648 457,648 457,648 Anti-dilutive shares

Segment information

Segment information	9 Months Ended
	Sep. 30, 2023
Segment Information
Segment information	9. Segment information The Company operates in a single operating segment, being the biopharmaceutical segment. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Commitments

Commitments	9 Months Ended
	Sep. 30, 2023
Commitments
Commitments	10. Commitments Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 6,857 1 - 3 years 131 4 - 5 years 36 More than 5 years - Total 7,024 In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $ 38,127

Basis of presentation (Policies

Basis of presentation (Policies)	9 Months Ended
	Sep. 30, 2023
Basis Of Presentation
New standards and amendments	New standards and amendments Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.
Critical accounting estimates and judgements	Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Aeterna Zentaris Inc. Notes to the Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue [abstract]
Summary of revenue from transfer of goods and services	The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories: Summary of revenue from transfer of goods and services 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ License fees - 605 1,554 831 Development services - 1,202 2,741 2,091 Product sales - - - 57 Royalties 3 14 29 57 Supply chain - 39 53 119 Total revenue 3 1,860 4,377 3,155
Summary of deferred revenue	The following table provides a summary of deferred revenue balances: Summary of deferred revenue September 30, 2023 Current Non-current Total $ $ $ Novo Nordisk Health Care - - - Pharmanovia 82 1,528 1,610 NK Meditech 8 119 127 90 1,647 1,737 December 31, 2022 Current Non-current Total $ $ $ Novo Nordisk Health Care 2,914 - 2,914 Consilient Health 35 1,556 1,591 NK Meditech - 128 128 2,949 1,684 4,633

Employee future benefits (Table

Employee future benefits (Tables)	9 Months Ended
	Sep. 30, 2023
Employee Future Benefits
Summary of net defined benefit liability asset	The change in the Company’s employee future benefit obligations is summarized as follows: Summary of net defined benefit liability asset benefit plans benefit plans Total Total Nine months ended September 30, 2023 Year ended December 31, 2022 Pension Other benefit plans benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 21,657 93 21,750 29,412 Current service cost 89 11 100 142 Interest cost 599 1 600 295 Actuarial gain from changes in financial assumptions (1,249 ) (1 ) (1,250 ) (5,915 ) Benefits paid (560 ) - (560 ) (752 ) Impact of foreign exchange rate changes (295 ) (2 ) (297 ) (1,432 ) Balances – End of the period 20,241 102 20,343 21,750 Change in plan assets Balances – Beginning of the period 10,591 - 10,591 11,927 Interest income from plan assets 296 - 296 120 Employer contributions 25 - 25 45 Employee contributions 7 - 7 10 Benefits paid (198 ) - (198 ) (247 ) Remeasurement of plan assets - - - (641 ) Change in asset ceiling (337 ) - (337 ) - Impact of foreign exchange rate changes (146 ) - (146 ) (623 ) Balances – End of the period 10,238 - 10,238 10,591 Net liability of the unfunded plans 10,003 102 10,105 10,787 Net liability of the funded plans - - - 372 Net amount recognized as Employee future benefits 10,003 102 10,105 11,159 Amounts recognized: In net loss 385 12 397 295 Actuarial gain on defined benefit plans in other comprehensive loss 912 1 913 5,262

Shareholders_ equity (Tables)

Shareholders’ equity (Tables)	9 Months Ended
	Sep. 30, 2023
Shareholders Equity
Summary of share capital	Summary of share capital Common shares Amount # $ Balance – December 31, 2022 4,855,876 293,410 - - Balance – September 30, 2023 4,855,876 293,410
Summary of assumptions to determine share-based compensation costs over the life of awards	Summary of assumptions to determine share-based compensation costs over the life of awards September 30, 2023 September 30, 2022 Expected dividend yield $ 0.00 $ 0.00 Expected volatility 104.46 % 115.75 % Risk-free annual interest rate 3.56 % 1.59 % Expected life (years) 5.45 5.72 Share price $ 3.75 $ 8.88 Exercise price $ 3.75 $ 8.88 Grant date fair value $ 2.99 $ 7.47
Summary of number and weighted average exercise prices of share options	Summary of number and weighted average exercise prices of share options Stock options Weighted average exercise price # $ Balance – January 1, 2023 42,030 20.05 Granted 14,000 3.75 Cancelled / Forfeited (400 ) 87.00 Balance – September 30, 2023 55,630 15.47 Stock options Weighted average exercise price # $ Balance – January 1, 2022 43,455 22.00 Granted 2,000 8.88 Cancelled / Forfeited (2,399 ) 10.98 Balance – September 30, 2022 43,056 21.95
Summary of DSU activity	Summary of DSU activity 2023 2022 # # Balance – January 1, 96,920 16,920 Granted 100,000 80,000 Balance – September 30, 196,920 96,920

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	9 Months Ended
	Sep. 30, 2023
Supplemental Disclosure Of Cash Flow Information
Disclosure of changes in operating assets and liabilities	Disclosure of changes in operating assets and liabilities 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables (411 ) 205 (9 ) 425 Inventory (1 ) 41 139 (165 ) Prepaid expenses and other current assets 186 (481 ) 64 (1,240 ) Payables and accrued liabilities (159 ) (133 ) (322 ) (14 ) Deferred revenues (27 ) 595 (1,386 ) 1,425 Taxes payable - 210 - 210 Provision for restructuring and other costs (6 ) - (11 ) - Employee future benefits (142 ) (269 ) (396 ) (387 ) Deferred gain 466 - 466 - Increase (decrease) in operating assets and liabilities (94 ) 168 (1,455 ) 254

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2023
Net Loss Per Share
Summary of pertinent data relating to computation of basic and diluted net loss per share	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of pertinent data relating to computation of basic and diluted net loss per share 2023 2022 2023 2022 Three months ended Nine months ended September 30, September 30, 2023 2022 2023 2022 $ $ $ $ Net loss (4,145 ) (3,420 ) (10,917 ) (10,276 ) Basic and diluted weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876 Basic and diluted loss per share (0.85 ) (0.70 ) (2.25 ) (2.12 ) Basic loss per share (0.85 ) (0.70 ) (2.25 ) (2.12 ) Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Stock options and DSUs 252,550 142,375 252,550 142,375 Warrants 457,648 457,648 457,648 457,648 Anti-dilutive shares

Commitments (Tables)

Commitments (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments
Schedule of expected future minimum lease payments	Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows: Schedule of expected future minimum lease payments TOTAL $ Less than 1 year 6,857 1 - 3 years 131 4 - 5 years 36 More than 5 years - Total 7,024

Summary of revenue from transfe

Summary of revenue from transfer of goods and services (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
IfrsStatementLineItems [Line Items]
Total revenue	$ 3	$ 1,860	$ 4,377	$ 3,155
License Fees [Member]
IfrsStatementLineItems [Line Items]
Total revenue		605	1,554	831
Development Services [Member]
IfrsStatementLineItems [Line Items]
Total revenue		1,202	2,741	2,091
Product Sales [Member]
IfrsStatementLineItems [Line Items]
Total revenue				57
Royalties [Member]
IfrsStatementLineItems [Line Items]
Total revenue	3	14	29	57
Supply Chain [Member]
IfrsStatementLineItems [Line Items]
Total revenue		$ 39	$ 53	$ 119

Summary of deferred revenue (De

Summary of deferred revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	$ 90	$ 2,949
Total Deferred Revenues Non Current	1,647	1,684
Total Deferred Revenues	1,737	4,633
Novo Nordisk Health Care [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues		2,914
Total Deferred Revenues Non Current
Total Deferred Revenues		2,914
Pharmanovia [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	82
Total Deferred Revenues Non Current	1,528
Total Deferred Revenues	1,610
NK Meditech [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	8
Total Deferred Revenues Non Current	119	128
Total Deferred Revenues	$ 127	128
Consilient Health [member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues		35
Total Deferred Revenues Non Current		1,556
Total Deferred Revenues		$ 1,591

Revenue (Details Narrative)

Revenue (Details Narrative) € in Thousands, $ in Thousands			3 Months Ended		9 Months Ended
	May 23, 2023 USD ($)	May 23, 2023 EUR (€)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 15, 2023 USD ($)	Mar. 15, 2023 EUR (€)
IfrsStatementLineItems [Line Items]
Revenue			$ 3	$ 1,860	$ 4,377	$ 3,155
Novo Nordisk Health Care AG [member]
IfrsStatementLineItems [Line Items]
Detect trial costs	$ 10,100	€ 9,400
Unsatisfied performance obligations [member]
IfrsStatementLineItems [Line Items]
Performance obligations							$ 1,658	€ 1,540
Indication performance obligation [member]
IfrsStatementLineItems [Line Items]
Performance obligations							1,233	1,145
Pediatric indication performance [member]
IfrsStatementLineItems [Line Items]
Performance obligations							$ 425	€ 395
Goods or services transferred over time [member]
IfrsStatementLineItems [Line Items]
Revenue				1,807	4,295	2,922
Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue			$ 3	$ 53	$ 82	$ 233

Deferred gain (Details Narrativ

Deferred gain (Details Narrative) $ in Thousands, € in Millions	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Aug. 10, 2021 USD ($)	Aug. 10, 2021 EUR (€)
Deferred Gain
Deferred gain	$ 529		$ 529	€ 0.5

Summary of net defined benefit

Summary of net defined benefit liability asset (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Change in plan liabilities
Balances – Beginning of the period	$ 21,750	$ 29,412
Current service cost	100	142
Interest cost	600	295
Actuarial gain from changes in financial assumptions	1,250	5,915
Benefits paid	(560)	(752)
Impact of foreign exchange rate changes	(297)	(1,432)
Balances – End of the period	20,343	21,750
Change in plan assets
Balances – Beginning of the period	10,591	11,927
Interest income from plan assets	296	120
Employer contributions	25	45
Employee contributions	7	10
Benefits paid	(198)	(247)
Remeasurement of plan assets		(641)
Change in asset ceiling	(337)
Impact of foreign exchange rate changes	(146)	(623)
Balances – End of the period	10,238	10,591
Net liability of the unfunded plans	10,105	10,787
Net liability of the funded plans		372
Net amount recognized as Employee future benefits	10,105	11,159
Amounts recognized:
In net loss	397	295
Actuarial gain on defined benefit plans in other comprehensive loss	913	5,262
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	21,657
Current service cost	89
Interest cost	599
Actuarial gain from changes in financial assumptions	1,249
Benefits paid	(560)
Impact of foreign exchange rate changes	(295)
Balances – End of the period	20,241	21,657
Change in plan assets
Balances – Beginning of the period	10,591
Interest income from plan assets	296
Employer contributions	25
Employee contributions	7
Benefits paid	(198)
Remeasurement of plan assets
Change in asset ceiling	(337)
Impact of foreign exchange rate changes	(146)
Balances – End of the period	10,238	10,591
Net liability of the unfunded plans	10,003
Net liability of the funded plans
Net amount recognized as Employee future benefits	10,003
Amounts recognized:
In net loss	385
Actuarial gain on defined benefit plans in other comprehensive loss	912
Other benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	93
Current service cost	11
Interest cost	1
Actuarial gain from changes in financial assumptions	1
Benefits paid
Impact of foreign exchange rate changes	(2)
Balances – End of the period	102	93
Change in plan assets
Balances – Beginning of the period
Interest income from plan assets
Employer contributions
Employee contributions
Benefits paid
Remeasurement of plan assets
Change in asset ceiling
Impact of foreign exchange rate changes
Balances – End of the period
Net liability of the unfunded plans	102
Net liability of the funded plans
Net amount recognized as Employee future benefits	102
Amounts recognized:
In net loss	12
Actuarial gain on defined benefit plans in other comprehensive loss	$ 1

Employee future benefits (Detai

Employee future benefits (Details Narrative)	Sep. 30, 2023	Dec. 31, 2022
Employee Future Benefits
Employee future benefit obligation	4.20%	3.75%

Summary of share capital (Detai

Summary of share capital (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
IfrsStatementLineItems [Line Items]
Balance	$ 35,776	$ 49,418	$ 52,986
Balance	$ 26,278	35,776	49,418
Issued capital [member]
IfrsStatementLineItems [Line Items]
Number of shares issued	4,855,876
Balance	$ 293,410	$ 293,410	293,410
Number of shares issued	4,855,876	4,855,876
Balance	$ 293,410	$ 293,410	$ 293,410

Summary of assumptions to deter

Summary of assumptions to determine share-based compensation costs over the life of awards (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Shareholders Equity
Expected dividend yield	0%	0%
Expected volatility	104.46%	115.75%
Risk-free annual interest rate	3.56%	1.59%
Expected life (years)	5 years 5 months 12 days	5 years 8 months 19 days
Share price	$ 3.75	$ 8.88
Exercise price	3.75	8.88
Grant date fair value	$ 2.99	$ 7.47

Summary of number and weighted

Summary of number and weighted average exercise prices of share options (Details)	9 Months Ended
	Sep. 30, 2023 shares $ / shares	Sep. 30, 2022 shares $ / shares
Shareholders Equity
Number of options, beginning | shares	42,030	43,455
Weighted average exercise price, beginning | $ / shares	$ 20.05	$ 22
Number of options, granted | shares	14,000	2,000
Weighted average exercise price, granted | $ / shares	$ 3.75	$ 8.88
Number of options, canceled/forfeited | shares	(400)	(2,399)
Weighted average exercise price, cancelled/forfeited | $ / shares	$ 87	$ 10.98
Number of options, ending | shares	55,630	43,056
Weighted average exercise price, ending | $ / shares	$ 15.47	$ 21.95

Summary of DSU activity (Detail

Summary of DSU activity (Details) - Deferred Share Unit [member] - shares			9 Months Ended
	Jun. 14, 2023	Jun. 14, 2022	Sep. 30, 2023	Sep. 30, 2022
IfrsStatementLineItems [Line Items]
Balance – January 1,			96,920	16,920
Granted	100,000	80,000	100,000	80,000
Balance – September 30,			196,920	96,920

Shareholders_ equity (Details N

Shareholders’ equity (Details Narrative) $ in Thousands						3 Months Ended		9 Months Ended
	Jun. 14, 2023 shares	Jan. 17, 2023 shares	Jul. 15, 2022	Jun. 14, 2022 shares	Jan. 17, 2022 shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($) shares
IfrsStatementLineItems [Line Items]
Number of options, granted								14,000	2,000
Compensation expenses | $						$ 27	$ 43	$ 66	$ 101
Deferred Share Unit [member]
IfrsStatementLineItems [Line Items]
Compensation expenses | $								$ 284	$ 402
Number of share units granted	100,000			80,000				100,000	80,000
2018 Long Term Incentive Plan [member]
IfrsStatementLineItems [Line Items]
Number of options, granted		14,000			2,000
Key management personnel of entity or parent [member]
IfrsStatementLineItems [Line Items]
Reverse stock split			1-for-25
Deferred Stock Units [member]
IfrsStatementLineItems [Line Items]
Reverse stock split			1-for-25

Disclosure of changes in operat

Disclosure of changes in operating assets and liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Supplemental Disclosure Of Cash Flow Information
Trade and other receivables	$ (411)	$ 205	$ (9)	$ 425
Inventory	(1)	41	139	(165)
Prepaid expenses and other current assets	186	(481)	64	(1,240)
Payables and accrued liabilities	(159)	(133)	(322)	(14)
Deferred revenues	(27)	595	(1,386)	1,425
Taxes payable		210		210
Provision for restructuring and other costs	(6)		(11)
Employee future benefits	(142)	(269)	(396)	(387)
Deferred gain	466		466
Increase (decrease) in operating assets and liabilities	$ (94)	$ 168	$ (1,455)	$ 254

Summary of pertinent data relat

Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
IfrsStatementLineItems [Line Items]
Net loss	$ (4,145)	$ (3,420)	$ (10,917)	$ (10,276)
Basic weighted-average shares outstanding	4,855,876	4,855,876	4,855,876	4,855,876
Diluted weighted-average shares outstanding	4,855,876	4,855,876	4,855,876	4,855,876
Basic loss per share	$ (0.85)	$ (0.70)	$ (2.25)	$ (2.12)
Diluted loss per share	$ (0.85)	$ (0.70)	$ (2.25)	$ (2.12)
Employee Stock Option One Deferred Stock Units [Member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Anti-dilutive shares	252,550	142,375	252,550	142,375
Warrants [member]
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Anti-dilutive shares	457,648	457,648	457,648	457,648

Schedule of expected future min

Schedule of expected future minimum lease payments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 7,024
Not later than one year [member]
IfrsStatementLineItems [Line Items]
Total	6,857
One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	131
Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	36
Later than five years [member]
IfrsStatementLineItems [Line Items]
Total

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Minimum lease payments net	$ 7,024
Top of range [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments net		$ 38,127